Ocumension Therapeutics And 2 SEHK Growth Stocks With Strong Insider Ownership
Reviewed by Simply Wall St
As global markets navigate a complex landscape of economic shifts, the Hong Kong market has experienced mixed performance, with the Hang Seng Index recently seeing a decline. In this environment, growth companies with high insider ownership can be particularly appealing to investors, as they often signal strong alignment between management and shareholder interests—an important consideration amid current market volatility.
Top 10 Growth Companies With High Insider Ownership In Hong Kong
| Name | Insider Ownership | Earnings Growth |
| Laopu Gold (SEHK:6181) | 36.4% | 33.2% |
| Akeso (SEHK:9926) | 20.5% | 53.1% |
| Fenbi (SEHK:2469) | 33.1% | 22.4% |
| Zylox-Tonbridge Medical Technology (SEHK:2190) | 18.8% | 69.8% |
| Pacific Textiles Holdings (SEHK:1382) | 11.2% | 37.7% |
| Ocumension Therapeutics (SEHK:1477) | 15.4% | 101.9% |
| Zhejiang Leapmotor Technology (SEHK:9863) | 15% | 70% |
| DPC Dash (SEHK:1405) | 38.1% | 104.8% |
| Beijing Airdoc Technology (SEHK:2251) | 29.4% | 93.4% |
| Biocytogen Pharmaceuticals (Beijing) (SEHK:2315) | 13.9% | 109.2% |
We'll examine a selection from our screener results.
Ocumension Therapeutics (SEHK:1477)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Ocumension Therapeutics, along with its subsidiaries, functions as an ophthalmic pharmaceutical platform company in the People's Republic of China and has a market cap of approximately HK$5.31 billion.
Operations: The company generates revenue of CN¥310.29 million from its activities in discovering, developing, and commercializing ophthalmic therapies.
Insider Ownership: 15.4%
Revenue Growth Forecast: 39.3% p.a.
Ocumension Therapeutics, a growth-focused company in Hong Kong with substantial insider ownership, is forecast to experience significant revenue growth at 39.3% annually, surpassing the broader market rate. Despite past shareholder dilution and current unprofitability, analysts anticipate profitability within three years and a potential stock price increase of 61.9%. Recent developments include drug approvals for OT-502 and OT-1001 in China, enhancing its product portfolio amid ongoing share repurchase activities aimed at improving financial metrics.
- Click here to discover the nuances of Ocumension Therapeutics with our detailed analytical future growth report.
- Our valuation report here indicates Ocumension Therapeutics may be undervalued.
Laopu Gold (SEHK:6181)
Simply Wall St Growth Rating: ★★★★★★
Overview: Laopu Gold Co., Ltd. designs, manufactures, and sells jewelry products in Mainland China, Hong Kong, and Macau with a market cap of HK$28.74 billion.
Operations: The company's revenue segment includes CN¥5.28 billion from Jewelry & Watches.
Insider Ownership: 36.4%
Revenue Growth Forecast: 24.5% p.a.
Laopu Gold, with substantial insider ownership, is forecast to achieve significant annual earnings growth of 33.2%, outpacing the Hong Kong market. Recent financials show a robust increase in net income to CNY 587.81 million for the first half of 2024, compared to CNY 196.75 million a year prior. Trading at a notable discount to its estimated fair value, Laopu Gold's revenue is also expected to grow significantly above market rates at 24.5% annually.
- Navigate through the intricacies of Laopu Gold with our comprehensive analyst estimates report here.
- According our valuation report, there's an indication that Laopu Gold's share price might be on the expensive side.
Akeso (SEHK:9926)
Simply Wall St Growth Rating: ★★★★★★
Overview: Akeso, Inc. is a biopharmaceutical company focused on researching, developing, manufacturing, and commercializing antibody drugs with a market cap of HK$58.01 billion.
Operations: The company generates revenue of CN¥1.87 billion from its activities in the research, development, production, and sale of biopharmaceutical products.
Insider Ownership: 20.5%
Revenue Growth Forecast: 33.5% p.a.
Akeso, characterized by high insider ownership, is projected to achieve substantial revenue growth of 33.5% annually, surpassing the Hong Kong market average. The company recently reported a net loss for H1 2024 amid strategic advancements in its oncology portfolio, including promising clinical results for cadonilimab and ebronucimab approvals. Despite past shareholder dilution and trading below estimated fair value, Akeso's innovative drug pipeline positions it for potential long-term profitability above market expectations.
- Click here and access our complete growth analysis report to understand the dynamics of Akeso.
- Our valuation report here indicates Akeso may be overvalued.
Make It Happen
- Unlock more gems! Our Fast Growing SEHK Companies With High Insider Ownership screener has unearthed 45 more companies for you to explore.Click here to unveil our expertly curated list of 48 Fast Growing SEHK Companies With High Insider Ownership.
- Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
- Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.
Looking For Alternative Opportunities?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About SEHK:9926
Akeso
A biopharmaceutical company, researches, develops, manufactures, and commercializes antibody drugs.
Exceptional growth potential with adequate balance sheet.
